DEFA14A: Onconova and Trawsfynydd Merge to Form Traws Pharma, Focusing on Virology and Oncology

Onconova Therapeutics and Trawsfynydd Therapeutics have merged to create Traws Pharma, a company focused on developing antiviral and oncology treatments, backed by a $14 million private placement.

Summary

• Onconova Therapeutics and Trawsfynydd Therapeutics have completed a merger, forming Traws Pharma, Inc., which will trade on NASDAQ under the ticker TRAW starting April 3, 2024.
• Traws Pharma secured a $14 million private placement led by OrbiMed and Torrey Pines, expecting a closing cash balance of approximately $28 million.
• The combined company will focus on advancing three assets: viroksavir for influenza, travaltrelvir for COVID-19, and narazaciclib for low grade endometrioid endometrial cancer (LGEEC).
• Multiple near-term catalysts are expected for viroksavir and travaltrevir in 2024, with topline data expected in H2 2024.
• Werner Cautreels, Ph.D., will lead Traws Pharma as CEO, with Iain Dukes, DPhil (OrbiMed), as Executive Chairman and Nikolay Savchuk, Ph.D. (Torrey Pines), as COO.
• Onconova stockholders as of April 15, 2024, will receive a contingent value right (CVR) for potential proceeds from the disposition or net sales of narazaciclib and rigosertib.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting the potential of the combined company and its pipeline. The successful closing of the merger and the private placement are also positive developments.

Positives

• The merger creates a company with a diversified pipeline in both virology and oncology.
• The $14 million private placement provides significant funding to advance key clinical programs.
• Experienced leadership team with expertise in drug development and investment.
• Potential for near-term clinical data catalysts in H2 2024.

Negatives

• The success of the combined company depends on the successful development and commercialization of its product candidates, which is inherently uncertain.
• The CVRs are contingent and may not result in any payments to Onconova stockholders.

Risks

• Clinical trial delays or failures could negatively impact the development of key assets.
• Regulatory hurdles and competition in the antiviral and oncology markets.
• The combined company may require additional funding in the future.
• Failure to achieve Requisite Stockholder Approval.

Future Outlook

The combined company will focus on advancing its pipeline of antiviral and oncology assets through clinical development and potential commercialization.

Management Comments

• Dr. Cautreels stated that Trawsfynydd is ready to initiate Phase 2 studies in H2 2024 for its lead antiviral programs for influenza and COVID19.
• Dr. Fruchtman commented that Trawsfynydd has a differentiated pipeline and an accomplished leadership team.

Industry Context

The merger reflects a trend in the biopharmaceutical industry to combine assets and expertise to create companies with broader pipelines and greater potential for success.

Comparison to Industry Standards

• Narazaciclib is positioned as a next-generation CDK4/6 inhibitor, potentially offering a better efficacy/safety ratio compared to approved products like palbociclib (Pfizer), ribociclib (Novartis), and abemaciclib (Lilly).
• Travaltrelvir is positioned as a potentially superior Mpro protease inhibitor for COVID19 compared to nirmatrelvir (Pfizers Mpro inhibitor, PAXLOVID) due to not requiring co-administration with a human cytochrome P450 (CYP) inhibitor such as ritonavir.

Management Changes

Stakeholder Impact

• Shareholders of Onconova will receive a CVR, providing potential upside from legacy assets.
• Employees of both companies will be integrated into the new organization.
• Patients may benefit from the development of new treatments for viral infections and cancer.

Next Steps

• Close the $14 million private placement.
• Initiate Phase 2 studies for viroksavir and travaltrelvir in H2 2024.
• Define the RP2D for narazaciclib.
• Obtain stockholder approval for the conversion of the Series C preferred stock.

Key Dates

Keywords

Merger, Traws Pharma, Onconova Therapeutics, Trawsfynydd Therapeutics, Viroksavir, Travaltrelvir, Narazaciclib, Private Placement, CVR, Antiviral, Oncology, Clinical Trials